|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM197045383 |
| 003 |
DE-627 |
| 005 |
20231223205740.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231223s2010 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2010.02.016
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0657.xml
|
| 035 |
|
|
|a (DE-627)NLM197045383
|
| 035 |
|
|
|a (NLM)20359955
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Arai, Takashi
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Administration of a determinant of preproinsulin can induce regulatory T cells and suppress anti-islet autoimmunity in NOD mice
|
| 264 |
|
1 |
|c 2010
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 06.08.2010
|
| 500 |
|
|
|a Date Revised 17.11.2011
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a (c) 2010 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Antigen-specific immunotherapy is expected to be an ideal strategy for treating type 1 diabetes (T1D). We investigated the therapeutic efficacy of a peptide in the leader sequence of preproinsulin, which was selected because of its binding affinity to the MHC I-A(g7) molecule. Preproinsulin-1 L7-24 peptide (L7-24) emulsified in Freund's incomplete adjuvant was administered subcutaneously to NOD mice. Administration of L7-24 increased the proportion of regulatory T cells in the spleen. Splenocytes of NOD mice immunized with this peptide secreted IL-4 and IL-10 in response to L7-24. This peptide also significantly prevented the development of diabetes and cured some newly diabetic NOD mice without recurrence. L7-24 peptide, which has a high affinity for pockets of I-A(g7), induced regulatory T cells and showed therapeutic effects. This peptide may provide a new approach for developing antigen-specific immunotherapy for autoimmune diabetes
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Blood Glucose
|2 NLM
|
| 650 |
|
7 |
|a Forkhead Transcription Factors
|2 NLM
|
| 650 |
|
7 |
|a Foxp3 protein, mouse
|2 NLM
|
| 650 |
|
7 |
|a Histocompatibility Antigens Class II
|2 NLM
|
| 650 |
|
7 |
|a Insulin
|2 NLM
|
| 650 |
|
7 |
|a Peptide Fragments
|2 NLM
|
| 650 |
|
7 |
|a Protein Precursors
|2 NLM
|
| 650 |
|
7 |
|a Transforming Growth Factor beta
|2 NLM
|
| 650 |
|
7 |
|a Concanavalin A
|2 NLM
|
| 650 |
|
7 |
|a 11028-71-0
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-10
|2 NLM
|
| 650 |
|
7 |
|a 130068-27-8
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-4
|2 NLM
|
| 650 |
|
7 |
|a 207137-56-2
|2 NLM
|
| 650 |
|
7 |
|a preproinsulin
|2 NLM
|
| 650 |
|
7 |
|a 61116-24-3
|2 NLM
|
| 650 |
|
7 |
|a Interferon-gamma
|2 NLM
|
| 650 |
|
7 |
|a 82115-62-6
|2 NLM
|
| 700 |
1 |
|
|a Moriyama, Hiroaki
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shimizu, Mami
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sasaki, Hirotomo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kishi, Minoru
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Okumachi, Yasuyo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yasuda, Hisafumi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hara, Kenta
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yokono, Koichi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nagata, Masao
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 136(2010), 1 vom: 03. Juli, Seite 74-82
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:136
|g year:2010
|g number:1
|g day:03
|g month:07
|g pages:74-82
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2010.02.016
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 136
|j 2010
|e 1
|b 03
|c 07
|h 74-82
|